Sarah Letemplier

Sarah Letemplier has a diverse work experience spanning several industries and roles. Sarah currently serves as the Chief Executive Officer at Perha Pharmaceuticals, a position they have held since April 2023. Prior to this, they were the Chief Financial Officer at Perha Pharmaceuticals from July 2019 to March 2023.

Before joining Perha Pharmaceuticals, Sarah worked as the Chief Financial Officer at ManRos Therapeutics from January 2017 to March 2023. Sarah has also gained experience in investment banking as an Investment Banking Autumn Analyst at Credit Suisse from September 2016 to December 2016.

Sarah's earlier roles include serving as a Junior Investment Manager at Investisseurs & Partenaires - I&P from May 2016 to August 2016, Treasurer at Transaction EM Lyon from January 2015 to December 2015, Risk and Control Analyst at Agence France Locale from June 2015 to September 2015, Assistant Manager at La Bastide de France from June 2014 to December 2014, and Consultant of the Financial Director at Mann & Noble from July 2014 to September 2014.

Overall, Sarah Letemplier's work experience demonstrates their expertise in finance and management roles in various industries.

Sarah Letemplier obtained their high school diploma in Science with honors from Lycée Emile Zola from 2008 to 2011. Sarah then pursued a classe préparatoire économique voie scientifique at Lycée Saint-Louis, Paris VI from 2011 to 2013. Sarah continued their education at Université Lumière Lyon 2 from 2015 to 2016, where they earned a Bachelor's degree in Business Law. Finally, they attended emlyon business school from 2013 to 2017, completing a Master of Science (MSc) in Management.